BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

airPharma Adds Executives In Corporate & Product Development


10/19/2005 5:12:20 PM

OVERLAND PARK, Kan., Nov. 30 /PRNewswire/ -- airPharma, a specialty pharmaceutical company focused on commercializing products that address unmet needs in respiratory diseases, today announced it has added two experienced pharmaceutical executives to the company's management team. Peter T. Higuchi has joined airPharma as Vice President, Corporate Development, and Ed Mitchell, Ph.D., has joined as Vice President, Product Development.

"As airPharma moves from the startup stage to commercialization, we've assembled a team with the experience and drive to build a valuable pipeline of drugs for respiratory diseases. We are very pleased to announce the hiring of Ed Mitchell and Peter Higuchi, seasoned experts who can carry airPharma forward in our drug development and strategic alliances," said Doug Dockhorn, President and Chief Executive Officer of airPharma.

Mr. Higuchi is spearheading product licensing and strategic alliances for airPharma, bringing more than 20 years of experience in related fields. Previously, he was president and Chief Executive Officer of CyDex, Inc., a specialty pharmaceutical company focused on applications of drug delivery technology. Mr. Higuchi founded CyDex in 1993, built a team of scientists and staff, and forged numerous corporate alliances to create a pipeline of pharmaceutical products. Mr. Higuchi also has served as a member of the Board of Directors of various pharmaceutical organizations.

In previous ventures, Mr. Higuchi consulted in corporate finance, technology transfer and business development as President of Higuchi & Co; worked in licensing and corporate development for Marion Laboratories and Marion Merrell Dow; and was a consultant with Touche Ross & Co. He holds a B.A. from the University of Kansas, a J.D. from Washburn University School of Law and an M.I.M. from the American Graduate School of International Management.

Dr. Mitchell leads airPharma's product development team, drawing on more than 30 years of drug development and regulatory management experience. Most recently, he was North American Head of Industrial Operations Chemistry Manufacturing and Controls (CMC) for Aventis Pharmaceuticals. Previously, Dr. Mitchell was Director of Product Development Services for PRA International, responsible for development strategy for several respiratory products. In prior positions, he served as Chief Regulatory Officer for Oread, Inc.; Vice President of U.S. Regulatory Affairs for IVAX Corporation; and a number of positions in drug development and regulatory affairs for Marion Laboratories and Marion Merrell Dow.

Dr. Mitchell's experience encompasses products in a broad range of therapeutic areas, including respiratory/pulmonary. He has interacted directly with the FDA as liaison for the approval and ongoing marketing of several products, including branded and generic drugs for respiratory and allergic diseases. Dr. Mitchell has been an author on numerous scientific publications and has served as an expert for FDA review of NDAs in the dental drug market. He received bachelor's degrees in Biology and Education from Kansas State University and a Ph.D. in Pharmacology and Physiology from the University of Missouri-Kansas City.

About airPharma

airPharma is a specialty pharmaceutical company focused on commercializing products that address unmet needs in respiratory diseases. The company is developing a portfolio of branded respiratory products. The company was founded in 2002 by Dr. Robert Dockhorn and Doug Dockhorn. Prior to airPharma, the Dockhorns built their previous company, IMTCI, into the leader in conducting respiratory clinical studies. airPharma is privately held and is located in Overland Park, KS. For further information, visit airPharma's website at http://www.air-pharma.com/ .

airPharma

CONTACT: Media, James A. Byrnes, Executive Vice President, GlobalCommercialization, of airPharma, +1-913-498-0700, jim.byrnes@air-pharma.com



Read at BioSpace.com

airPharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES